Alzheimer’s Research Papers Nov 2001

Alzheimer’s Research Papers Nov 2001

           

Wettstein A. [Differentiating between Alzheimer disease and vascular dementia? Currently no longer significant] Fortschr Med Orig. 2001 Nov 29;119(3-4):139-40.

Padberg F, Hampel H, Möller HJ. [Alzheimer patients treated with anti-dementia drugs despite unanswered questions] Fortschr Med Orig. 2001 Nov 29;119(3-4):141-3.

Schreiter Gasser U, Gasser T. [A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia] Fortschr Med Orig. 2001 Nov 29;119(3-4):135-8.

Martínez-Mir A, Cañestro C, Gonzàlez-Duarte R, Albalat R. Characterization of the amphioxus presenilin gene in a high gene-density genomic region illustrates duplication during the vertebrate lineage. Gene. 2001 Nov 28;279(2):157-64.

Silverberg GD, Heit G, Huhn S, Jaffe RA, Chang SD, Bronte-Stewart H, Rubenstein E, Possin K, Saul TA. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology. 2001 Nov 27;57(10):1763-6.

Goldstein FC, Ashley AV, Gearing M, Hanfelt J, Penix L, Freedman LJ, Levey AI. Apolipoprotein E and age at onset of Alzheimer's disease in African American patients. Neurology. 2001 Nov 27;57(10):1923-5.

Lleó A, Blesa R, Gendre J, Castellví M, Pastor P, Queralt R, Oliva R. A novel presenilin 2 gene mutation (D439A) in a patient with early-onset Alzheimer's disease. Neurology. 2001 Nov 27;57(10):1926-8.

Verreault R, Laurin D, Lindsay J, De Serres G. Past exposure to vaccines and subsequent risk of Alzheimer's disease. CMAJ. 2001 Nov 27;165(11):1495-8.

Hu Y, He S, Wang J. [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease] Zhonghua Yi Xue Za Zhi. 2001 Nov 25;81(22):1377-9.

Uversky VN, Lee HJ, Li J, Fink AL, Lee SJ. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem. 2001 Nov 23;276(47):43495-8.

Hill M, Lapcík O, Havlíková H, Morfin R, Hampl R. 7-Hydroxydehydroepiandrosterone epimers in human serum and saliva. Comparison of gas chromatography-mass spectrometry and radioimmunoassay. J Chromatogr A. 2001 Nov 23;935(1-2):297-307.

Ghiso JA, Holton J, Miravalle L, Calero M, Lashley T, Vidal R, Houlden H, Wood N, Neubert TA, Rostagno A, Plant G, Revesz T, Frangione B. Systemic amyloid deposits in familial British dementia. J Biol Chem. 2001 Nov 23;276(47):43909-14.

Beyer K, Lao JI, Gómez M, Riutort N, Latorre P, Mate JL, Ariza A. Alzheimer's disease and the cystatin C gene polymorphism: an association study. Neurosci Lett. 2001 Nov 23;315(1-2):17-20. ,

Brunelli T, Bagnoli S, Giusti B, Nacmias B, Pepe G, Sorbi S, Abbate R. The C677T methylenetetrahydrofolate reductase mutation is not associated with Alzheimer's disease. Neurosci Lett. 2001 Nov 23;315(1-2):103-5. ,

Yu Q, Holloway HW, Flippen-Anderson JL, Hoffman B, Brossi A, Greig NH. Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. J Med Chem. 2001 Nov 22;44(24):4062-71.

Breitner JC, Zandi PP. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease? N Engl J Med. 2001 Nov 22;345(21):1567-8.

  

in t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001 Nov 22;345(21):1515-21.

    

Yamada M, Lamping KG, Duttaroy A, Zhang W, Cui Y, Bymaster FP, McKinzie DL, Felder CC, Deng CX, Faraci FM, Wess J. Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):14096-101.

Kitazume S, Tachida Y, Oka R, Shirotani K, Saido TC, Hashimoto Y. Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13554-9.

 

Annaert WG, Esselens C, Baert V, Boeve C, Snellings G, Cupers P, Craessaerts K, De Strooper B. Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. Neuron. 2001 Nov 20;32(4):579-89.

    

Katayama T, Imaizumi K, Honda A, Yoneda T, Kudo T, Takeda M, Mori K, Rozmahel R, Fraser P, George-Hyslop PS, Tohyama M. Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer's disease-linked presenilin-1 mutations. J Biol Chem. 2001 Nov 16;276(46):43446-54.

 

Koudinov AR, Berezov TT, Koudinova NV. The levels of soluble amyloid beta in different high density lipoprotein subfractions distinguish Alzheimer's and normal aging cerebrospinal fluid: implication for brain cholesterol pathology? Neurosci Lett. 2001 Nov 16;314(3):115-8.

 

Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, Schleuder D, Jahn H, Rüther E, Kornhuber J, Annaert W, De Strooper B, Saftig P. Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J Biol Chem. 2001 Nov 16;276(46):42645-57.

Wilms H, Rosenstiel P, Sievers J, Deuschl G, Lucius R. Cerebrospinal fluid from patients with neurodegenerative and neuroinflammatory diseases: no evidence for rat glial activation in vitro. Neurosci Lett. 2001 Nov 16;314(3):107-10.

Pike CJ. Testosterone attenuates beta-amyloid toxicity in cultured hippocampal neurons. Brain Res. 2001 Nov 16;919(1):160-5.

Yasojima K, McGeer EG, McGeer PL. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 2001 Nov 16;919(1):115-21. ,

 

García Gil ML, Morán MA, Gómez-Ramos P. Ubiquitinated granular structures and initial neurofibrillary changes in the human brain. J Neurol Sci. 2001 Nov 15;192(1-2):27-34.

Athan ES, Williamson J, Ciappa A, Santana V, Romas SN, Lee JH, Rondon H, Lantigua RA, Medrano M, Torres M, Arawaka S, Rogaeva E, Song YQ, Sato C, Kawarai T, Fafel KC, Boss MA, Seltzer WK, Stern Y, St George-Hyslop P, Tycko B, Mayeux R. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA. 2001 Nov 14;286(18):2257-63. ,

Russ C, Powell JF, Zhao J, Baker M, Hutton M, Crawford F, Mullan M, Roks G, Cruts M, Lovestone S. The microtubule associated protein Tau gene and Alzheimer's disease--an association study and meta-analysis. Neurosci Lett. 2001 Nov 13;314(1-2):92-6. ,

Moreno-Flores MT, Martín-Aparicio E, Salinero O, Wandosell F. Fibronectin modulation by A beta amyloid peptide (25-35) in cultured astrocytes of newborn rat cortex. Neurosci Lett. 2001 Nov 13;314(1-2):87-91.

Alagona G, Bella R, Ferri R, Carnemolla A, Pappalardo A, Costanzo E, Pennisi G. Transcranial magnetic stimulation in Alzheimer disease: motor cortex excitability and cognitive severity. Neurosci Lett. 2001 Nov 13;314(1-2):57-60.

Bogdanovic N, Bretillon L, Lund EG, Diczfalusy U, Lannfelt L, Winblad B, Russell DW, Björkhem I. On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett. 2001 Nov 13;314(1-2):45-8.

 

Sjögren M, Gisslén M, Vanmechelen E, Blennow K. Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci Lett. 2001 Nov 13;314(1-2):33-6.

Rieder CR, Fricke D. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology. 2001 Nov 13;57(9):1742-3.

Hiltunen M, Mannermaa A, Thompson D, Easton D, Pirskanen M, Helisalmi S, Koivisto AM, Lehtovirta M, Ryynänen M, Soininen H. Genome-wide linkage disequilibrium mapping of late-onset Alzheimer's disease in Finland. Neurology. 2001 Nov 13;57(9):1663-8.

Warner J, Butler R. Drugs for Alzheimer's disease. More effective agents are needed. BMJ. 2001 Nov 10;323(7321):1127-8.

Noble JM. Drugs for Alzheimer's disease. Guidelines for prescribing cholinesterase inhibitors in Australia are similar to those in UK. BMJ. 2001 Nov 10;323(7321):1128.

Bradbury J. New mechanism proposed for NSAID reduction of Alzheimer's disease incidence. Lancet. 2001 Nov 10;358(9293):1616.

Wang SS, Rymer DL, Good TA. Reduction in cholesterol and sialic acid content protects cells from the toxic effects of beta-amyloid peptides. J Biol Chem. 2001 Nov 9;276(45):42027-34.

Tominaga-Yoshino K, Uetsuki T, Yoshikawa K, Ogura A. Neurotoxic and neuroprotective effects of glutamate are enhanced by introduction of amyloid precursor protein cDNA. Brain Res. 2001 Nov 9;918(1-2):121-30.

Rampa A, Piazzi L, Belluti F, Gobbi S, Bisi A, Bartolini M, Andrisano V, Cavrini V, Cavalli A, Recanatini M, Valenti P. Acetylcholinesterase inhibitors: SAR and kinetic studies on omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyaryl derivatives. J Med Chem. 2001 Nov 8;44(23):3810-20.

Gunawardena S, Goldstein LS. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron. 2001 Nov 8;32(3):389-401.

 

   

Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001 Nov 8;414(6860):212-6.

    

Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA. 2001 Nov 7;286(17):2120-7.

 

Cruts M, Dermaut B, Rademakers R, Roks G, van den Broeck M, Munteanu G, van Duijn CM, van Broeckhoven C. Amyloid beta secretase gene (BACE) is neither mutated in nor associated with early-onset Alzheimer's disease. Neurosci Lett. 2001 Nov 2;313(1-2):105-7. ,

Houlden H, Crook R, Dolan RJ, McLaughlin J, Revesz T, Hardy J. A novel presenilin mutation (M233V) causing very early onset Alzheimer's disease with Lewy bodies. Neurosci Lett. 2001 Nov 2;313(1-2):93-5.

Hokoishi K, Ikeda M, Maki N, Nebu A, Shigenobu K, Fukuhara R, Komori K, Tanabe H. Frontotemporal lobar degeneration: a study in Japan. Dement Geriatr Cogn Disord. 2001 Nov-Dec;12(6):393-9.

Zesiewicz TA, Baker MJ, Dunne PB, Hauser RA. Diffuse Lewy Body Disease. Curr Treat Options Neurol. 2001 Nov;3(6):507-518.

Tomoeda CK. Comprehensive assessment for dementia: a necessity for differential diagnosis and management. Semin Speech Lang. 2001 Nov;22(4):275-88; quiz 289.

Young KW, Greenwood CE. Shift in diurnal feeding patterns in nursing home residents with Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2001 Nov;56(11):M700-6.

Hébert R, Dubois MF, Wolfson C, Chambers L, Cohen C. Factors associated with long-term institutionalization of older people with dementia: data from the Canadian Study of Health and Aging. J Gerontol A Biol Sci Med Sci. 2001 Nov;56(11):M693-9.

Reynish W, Andrieu S, Nourhashemi F, Vellas B. Nutritional factors and Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2001 Nov;56(11):M675-80.

Dalle-Donne I, Rossi R, Giustarini D, Gagliano N, Lusini L, Milzani A, Di Simplicio P, Colombo R. Actin carbonylation: from a simple marker of protein oxidation to relevant signs of severe functional impairment. Free Radic Biol Med. 2001 Nov 1;31(9):1075-83.

Clarke NJ, Crow FW, Younkin S, Naylor S. Analysis of in vivo-derived amyloid-beta polypeptides by on-line two-dimensional chromatography-mass spectrometry. Anal Biochem. 2001 Nov 1;298(1):32-9.

Kato T. The other, forgotten genome: mitochondrial DNA and mental disorders. Mol Psychiatry. 2001 Nov;6(6):625-33.

Pompei P, Severini R, Pediconi D, Angeletti M, Eleuteri A, Fattoretti P, Bertoni-Freddari C, Fioretti E. Regulation of preprotachykinin-A gene expression in an animal model of Alzheimer's disease. J Histochem Cytochem. 2001 Nov;49(11):1469-70.

Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):589-95.

Yoshita M, Taki J, Yamada M. A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):583-8.

Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001 Nov 1;21(21):8370-7. ,

    

Kinoshita A, Whelan CM, Smith CJ, Mikhailenko I, Rebeck GW, Strickland DK, Hyman BT. Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein receptor-related protein and the amyloid precursor protein: role of the intracellular adapter protein Fe65. J Neurosci. 2001 Nov 1;21(21):8354-61.

 

Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, Sjögren M, Wallin A, Xilinas M, Gottfries CG. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord. 2001 Nov-Dec;12(6):408-14.

Scherder E, Bouma A, Slaets J, Ooms M, Ribbe M, Blok A, Sergeant J. Repeated pain assessment in Alzheimer's disease. Dement Geriatr Cogn Disord. 2001 Nov-Dec;12(6):400-7.

Lautenschlager NT, Riemenschneider M, Drzezga A, Kurz AF. Primary degenerative mild cognitive impairment: study population, clinical, brain imaging and biochemical findings. Dement Geriatr Cogn Disord. 2001 Nov-Dec;12(6):379-86.

Kontush A. Amyloid-beta: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic Biol Med. 2001 Nov 1;31(9):1120-31.

Iga JI, Araki M, Ishimoto Y, Ohmori T. A case of Korsakoff's syndrome improved by high doses of donepezil. Alcohol Alcohol. 2001 Nov-Dec;36(6):553-5.

Robinson KM, Adkisson P, Weinrich S. Problem behaviour, caregiver reactions, and impact among caregivers of persons with Alzheimer's disease. J Adv Nurs. 2001 Nov;36(4):573-82.

Parnetti L, Amici S, Lanari A, Gallai V. Pharmacological treatment of non-cognitive disturbances in dementia disorders. Mech Ageing Dev. 2001 Nov;122(16):2063-9.

Hopper T. Indirect interventions to facilitate communication in Alzheimer's disease. Semin Speech Lang. 2001 Nov;22(4):305-15.

Mahendra N. Direct interventions for improving the performance of individuals with Alzheimer's disease. Semin Speech Lang. 2001 Nov;22(4):291-303; quiz 304.

Ueki A, Iwado H, Shinjo H, Morita Y. [Malignant syndrome caused by a combination of bromperidol and donepezil hydrochloride in a patient with probable dementia with Lewy bodies] Nippon Ronen Igakkai Zasshi. 2001 Nov;38(6):822-4.

Argüelles T, Loewenstein D, Argüelles S. The impact of the native language of Alzheimer's disease and normal elderly individuals on their ability to recall digits. Aging Ment Health. 2001 Nov;5(4):358-65.

Sullivan K, O'Conor F. Should a diagnosis of Alzheimer's disease be disclosed? Aging Ment Health. 2001 Nov;5(4):340-8.

Shua-Haim JR, Haim T, Shi Y, Kuo YH, Smith JM. Depression among Alzheimer's caregivers: identifying risk factors. Am J Alzheimers Dis Other Demen. 2001 Nov-Dec;16(6):353-9.

Mucke H. TAK-147 (Takeda). Curr Opin Investig Drugs. 2001 Nov;2(11):1595-9.

Baumann P, Eap CB, Zullino DF. Fluvoxamine and perphenazine for psychosis in Alzheimer's disease: pharmacokinetic considerations. J Nerv Ment Dis. 2001 Nov;189(11):798-9.

Arendash GW, Gordon MN, Diamond DM, Austin LA, Hatcher JM, Jantzen P, DiCarlo G, Wilcock D, Morgan D. Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol. 2001 Nov;20(11):737-44.

Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW, Jantzen PT, Connor KE, Melachrino J, Hardy J, Morgan D. Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. 2001 Nov;20(11):731-6.

Vehmas AK, Borchelt DR, Price DL, McCarthy D, Wills-Karp M, Peper MJ, Rudow G, Luyinbazi J, Siew LT, Troncoso JC. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip technology. DNA Cell Biol. 2001 Nov;20(11):713-21.

Lemere CA, Maron R, Selkoe DJ, Weiner HL. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol. 2001 Nov;20(11):705-11.

 

Schenk D, Seubert P, Ciccarelli RB. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol. 2001 Nov;20(11):679-81.

 

Kowalski JW, Gawel M, Pfeffer A, Barcikowska M. The diagnostic value of EEG in Alzheimer disease: correlation with the severity of mental impairment. J Clin Neurophysiol. 2001 Nov;18(6):570-5.

Thatte U. NS-2330 (Neurosearch). Curr Opin Investig Drugs. 2001 Nov;2(11):1592-4.

Dermaut B, Roks G, Theuns J, Rademakers R, Houwing-Duistermaat JJ, Serneels S, Hofman A, Breteler MM, Cruts M, van Broeckhoven C, van Duijn CM. Variable expression of presenilin 1 is not a major determinant of risk for late-onset Alzheimer's disease. J Neurol. 2001 Nov;248(11):935-9. ,

Mikol J, Polivka M. [Histological data in inflammatory myositis] Ann Med Interne (Paris). 2001 Nov;152(7):465-79.

Sobow TM, Maczkiewicz M, Kloszewska I. Tianeptine versus fluoxetine in the treatment of depression complicating Alzheimer's disease. Int J Geriatr Psychiatry. 2001 Nov;16(11):1108-1109.

Small GW, Chen ST, Komo S, Ercoli L, Miller K, Siddarth P, Kaplan A, Dorsey D, Lavretsky H, Saxena S, Bookheimer SY. Memory self-appraisal and depressive symptoms in people at genetic risk for Alzheimer's disease. Int J Geriatr Psychiatry. 2001 Nov;16(11):1071-1077.

Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, Breitner JC. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001 Nov;16(11):1043-1053.

Lyketsos CG, Breitner JC, Rabins PV. An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer's diseaseAn earlier version of this paper was presented at the 18 March, 2000 meeting of the FDA Psychopharmacological Drugs Advisory Committee. Int J Geriatr Psychiatry. 2001 Nov;16(11):1037-1042.

Kennedy GJ. Advances in the epidemiology of Alzheimer's disease: will empiricism improve the public's health? Int J Geriatr Psychiatry. 2001 Nov;16(11):1028-1029.

Espiritu DA, Rashid H, Mast BT, Fitzgerald J, Steinberg J, Lichtenberg PA. Depression, cognitive impairment and function in Alzheimer's disease. Int J Geriatr Psychiatry. 2001 Nov;16(11):1098-1103.

Meyers BS. The evolving typology of neuropsychiatric complications of Alzheimer's disease: the use of latent trait analysis. Int J Geriatr Psychiatry. 2001 Nov;16(11):1030-1032.

Styczynska M, Wasiak B, Luczywek E, Pfeffer A, Barcikowska M. [Alpha2-macroglobulin gene polymorphism in patients with Alzheimer's disease] Neurol Neurochir Pol. 2001 Nov-Dec;35(6):1013-20.

Christner C, Herdegen T, Fischer G. FKBP ligands as novel therapeutics for neurological disorders. Mini Rev Med Chem. 2001 Nov;1(4):377-97.

Zhu CQ, Cao XD. [Regulatory effect of tiaoxin recipe drug serum on animal's Alzheimer disease related tau protein phosphorylation] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001 Nov;21(11):834-6.

Zakzanis KK, Boulos MI. Posterior cortical atrophy. Neurolog. 2001 Nov;7(6):341-9.

Barak Y, Bodner E, Zemishlani H, Mirecki I, Aizenberg D. Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial. Arch Gerontol Geriatr. 2001 Nov;33(3):237-41.

Dunn BM. Overview of pepsin-like aspartic peptidases. Curr Protoc Protein Sci. 2001 Nov;Chapter 21:Unit 21.3.

Yazawa H, Yu ZX, Takeda , Le Y, Gong W, Ferrans VJ, Oppenheim JJ, Li CC, Wang JM. Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J. 2001 Nov;15(13):2454-62.

Lin H, Bhatia R, Lal R. Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J. 2001 Nov;15(13):2433-44.

 

Herrup K, Yang Y. Pictures in molecular medicine: contemplating Alzheimer's disease as cancer: a loss of cell-cycle control. Trends Mol Med. 2001 Nov;7(11):527.

Zermansky AJ, Bolognani F, Stone D, Cowsill CM, Morrissey G, Castro MG, Löwenstein PR. Towards global and long-term neurological gene therapy: unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS. Mol Ther. 2001 Nov;4(5):490-8.

Graf A, Wallner C, Schubert V, Willeit M, Wlk W, Fischer P, Kasper S, Neumeister A. The effects of light therapy on mini-mental state examination scores in demented patients. Biol Psychiatry. 2001 Nov 1;50(9):725-7.

Cataldo A, Rebeck GW, Ghetri B, Hulette C, Lippa C, van Broeckhoven C, van Duijn C, Cras P, Bogdanovic N, Bird T, Peterhoff C, Nixon R. Endocytic disturbances distinguish among subtypes of Alzheimer's disease and related disorders. Ann Neurol. 2001 Nov;50(5):661-5.

Karenberg A. [Early history of Pick's disease] Fortschr Neurol Psychiatr. 2001 Nov;69(11):545-50.

Morishima-Kawashima M, Ihara Y. [Recent advances in Alzheimer's disease] Seikagaku. 2001 Nov;73(11):1297-307.

Pyles RB. The association of herpes simplex virus and Alzheimer's disease: a potential synthesis of genetic and environmental factors. Herpes. 2001 Nov;8(3):64-8.

Volicer L, McKee A, Hewitt S. Dementia. Neurol Clin. 2001 Nov;19(4):867-85.

Koirala T R, Nakagaki K, Ishida T, Nonaka S, Morikawa S, Tabira T. Decreased expression of MAP-2 and GAD in the brain of cats infected with feline immunodeficiency virus. Tohoku J Exp Med. 2001 Nov;195(3):141-51.

Merlini G, Bellotti V, Andreola A, Palladini G, Obici L, Casarini S, Perfetti V. Protein aggregation. Clin Chem Lab Med. 2001 Nov;39(11):1065-75.

Müller MB, Lucassen PJ, Yassouridis A, Hoogendijk WJ, Holsboer F, Swaab DF. Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. Eur J Neurosci. 2001 Nov;14(10):1603-12.

Bidzan L. [The psychopathological symptoms of the preclinical stages of Alzheimer's disease] Psychiatr Pol. 2001 Nov-Dec;35(6):1019-32.

Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE. Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide. DNA Cell Biol. 2001 Nov;20(11):723-9.

Solomon B. Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease. DNA Cell Biol. 2001 Nov;20(11):697-703.

Loring JF, Wen X, Lee JM, Seilhamer J, Somogyi R. A gene expression profile of Alzheimer's disease. DNA Cell Biol. 2001 Nov;20(11):683-95.

Ugen KE, Morgan D. Alzheimer's disease: molecularly based immunotherapeutics. DNA Cell Biol. 2001 Nov;20(11):677-8.

Pérez-Tur J. [Presenilins in the genesis of Alzheimer s disease] Rev Neurol. 2001 Nov 16-30;33(10):967-72.

Cutler SJ, Hodgson LG. Correlates of personal concerns about developing Alzheimer's disease among middle-aged persons. Am J Alzheimers Dis Other Demen. 2001 Nov-Dec;16(6):335-43.

Bogardus ST. When should one stop cholinesterase inhibitors in patients with Alzheimer's disease? J Psychiatry Neurosci. 2001 Nov;26(5):425.

Clarke NA, Soininen H, Gustafson L, Minthon L, Alhainen K, Francis PT. Tacrine may alter APP-like protein levels in the lumbar CSF of Alzheimer patients. Int J Geriatr Psychiatry. 2001 Nov;16(11):1104-6.

Lyketsos CG, Breitner JC, Rabins PV. An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer's disease. Int J Geriatr Psychiatry. 2001 Nov;16(11):1037-42.

Meyers BS. The evolving typology of neuropsychiatric complications of Alzheimer's disease: the use of latent trait analysis. Int J Geriatr Psychiatry. 2001 Nov;16(11):1030-2.

Kennedy GJ. Advances in the epidemiology of Alzheimer's disease: will empiricism improve the public's health? Int J Geriatr Psychiatry. 2001 Nov;16(11):1028-9.

Sjögren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res. 2001 Nov 1;66(3):510-6. ,

Espiritu DA, Rashid H, Mast BT, Fitzgerald J, Steinberg J, Lichtenberg PA. Depression, cognitive impairment and function in Alzheimer's disease. Int J Geriatr Psychiatry. 2001 Nov;16(11):1098-103.

Small GW, Chen ST, Komo S, Ercoli L, Miller K, Siddarth P, Kaplan A, Dorsey D, Lavretsky H, Saxena S, Bookheimer SY. Memory self-appraisal and depressive symptoms in people at genetic risk for Alzheimer's disease. Int J Geriatr Psychiatry. 2001 Nov;16(11):1071-7.

Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, Breitner JC. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry. 2001 Nov;16(11):1043-53.

Vestling M, Wiehager B, Tanii H, Cowburn RF. Akt activity in presenilin 1 wild-type and mutation transfected human SH-SY5Y neuroblastoma cells after serum deprivation and high glucose stress. J Neurosci Res. 2001 Nov 1;66(3):448-56.

Vallée M, Mayo W, Le Moal M. Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain Res Brain Res Rev. 2001 Nov;37(1-3):301-12.

Sobow TM, Maczkiewicz M, Kloszewska I. Tianeptine versus fluoxetine in the treatment of depression complicating Alzheimer's disease. Int J Geriatr Psychiatry. 2001 Nov;16(11):1108-9.

Rainer M, Mucke HA, Krüger-Rainer C, Kraxberger E, Haushofer M, Jellinger KA. Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics. J Neural Transm. 2001 Nov;108(11):1327-33.

Werber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm. 2001 Nov;108(11):1319-25.

Canales JJ, Corbalán R, Montoliu C, Llansola M, Monfort P, Erceg S, Hernandez-Viadel M, Felipo V. Aluminium impairs the glutamate-nitric oxide-cGMP pathway in cultured neurons and in rat brain in vivo: molecular mechanisms and implications for neuropathology. J Inorg Biochem. 2001 Nov;87(1-2):63-9.

Croom J, Taylor IL. Neuropeptide Y, peptide YY and aluminum in Alzheimer's disease: is there an etiological relationship? J Inorg Biochem. 2001 Nov;87(1-2):51-6.

Sobów TM, Kloszewska I. [Risperidone in the ambulatory treatment of behavior disorders in demented patients of Alzheimer's type: a retrospective analysis] Psychiatr Pol. 2001 Nov-Dec;35(6):1033-45.

Foy MR. 17beta-estradiol: effect on CA1 hippocampal synaptic plasticity. Neurobiol Learn Mem. 2001 Nov;76(3):239-52.

Leech RW, Brumback RA, Poduslo SE, Schiffer R, Adesina A. Dementia: the University of Oklahoma autopsy experience. J Okla State Med Assoc. 2001 Nov;94(11):507-11.

Axelsson S. The basic reality of mind and spongiform diseases. Med Hypotheses. 2001 Nov;57(5):549-54.

Cummings TJ, Strum JC, Yoon LW, Szymanski MH, Hulette CM. Recovery and expression of messenger RNA from postmortem human brain tissue. Mod Pathol. 2001 Nov;14(11):1157-61.

Foy CJ, Ardill J, Filmore D, Lawson JT, Passmore AP. Plasma somatostatin and gastrointestinal peptides in Alzheimer's disease and vascular dementia. QJM. 2001 Nov;94(11):631-5.

Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem. 2001 Nov;79(3):595-605.

Dingwall C. Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease. J Clin Invest. 2001 Nov;108(9):1243-6.

Liao GS, Li XB, Zhang CY, Shu YY, Tang SX. Pharmacological actions of nerve growth factor-transferrin conjugate on the central nervous system. J Nat Toxins. 2001 Nov;10(4):291-7.

Olivieri G, Hess C, Savaskan E, Ly C, Meier F, Baysang G, Brockhaus M, Müller-Spahn F. Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased beta-amyloid secretion. J Pineal Res. 2001 Nov;31(4):320-5.

Pearson VE. Galantamine: a new alzheimer drug with a past life. Ann Pharmacother. 2001 Nov;35(11):1406-13.

Uchihara T, Nakamura A, Yamazaki M, Mori O, Ikeda K, Tsuchiya K. Different conformation of neuronal tau deposits distinguished by double immunofluorescence with AT8 and thiazin red combined with Gallyas method. Acta Neuropathol (Berl). 2001 Nov;102(5):462-6.

Postiglione A, Milan G, Ruocco A, Gallotta G, Guiotto G, Di Minno G. Plasma folate, vitamin B(12), and total homocysteine and homozygosity for the C677T mutation of the 5,10-methylene tetrahydrofolate reductase gene in patients with Alzheimer's dementia. A case-control study. Gerontology. 2001 Nov-Dec;47(6):324-9. ,

Riek R, Güntert P, Döbeli H, Wipf B, Wüthrich K. NMR studies in aqueous solution fail to identify significant conformational differences between the monomeric forms of two Alzheimer peptides with widely different plaque-competence, A beta(1-40)(ox) and A beta(1-42)(ox). Eur J Biochem. 2001 Nov;268(22):5930-6.

Paschen W, Frandsen A. Endoplasmic reticulum dysfunction--a common denominator for cell injury in acute and degenerative diseases of the brain? J Neurochem. 2001 Nov;79(4):719-25.

Zhuang ZP, Kung MP, Hou C, Plössl K, Skovronsky D, Gur TL, Trojanowski JQ, Lee VM, Kung HF. IBOX(2-(4'-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. Nucl Med Biol. 2001 Nov;28(8):887-94.

Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol. 2001 Nov;65(4):391-426.

Fritsch T, McClendon MJ, Smyth KA, Lerner AJ, Chen CH, Petot GJ, Debanne SM, Soas A, Friedland RP. Effects of educational attainment on the clinical expression of Alzheimer's disease: results from a research registry. Am J Alzheimers Dis Other Demen. 2001 Nov-Dec;16(6):369-76.

Kontush A, Donarski N, Beisiegel U. Resistance of human cerebrospinal fluid to in vitro oxidation is directly related to its amyloid-beta content. Free Radic Res. 2001 Nov;35(5):507-17.

Moosmann B, Skutella T, Beyer K, Behl C. Protective activity of aromatic amines and imines against oxidative nerve cell death. Biol Chem. 2001 Nov;382(11):1601-12.

Prange A, Schaumlöffel D, Brätter P, Richarz AN, Wolf C. Species analysis of metallothionein isoforms in human brain cytosols by use of capillary electrophoresis hyphenated to inductively coupled plasma-sector field mass spectrometry. Fresenius J Anal Chem. 2001 Nov;371(6):764-74.

Fleischman DA, Monti LA, Dwornik LM, Moro TT, Bennett DA, Gabrieli JD. Impaired production priming and intact identification priming in Alzheimer's disease. J Int Neuropsychol Soc. 2001 Nov;7(7):785-94.

Gould R, Abramson I, Galasko D, Salmon D. Rate of cognitive change in Alzheimer's disease: methodological approaches using random effects models. J Int Neuropsychol Soc. 2001 Nov;7(7):813-24.

Crutch SJ, Warrington EK. Acalculia: deficits of operational and quantity number knowledge. J Int Neuropsychol Soc. 2001 Nov;7(7):825-34.

Ashe KH. Learning and memory in transgenic mice modeling Alzheimer's disease. Learn Mem. 2001 Nov-Dec;8(6):301-8.

Tabira T. [Progress in Alzheimer research] Nippon Ronen Igakkai Zasshi. 2001 Nov;38(6):723-34.

Michikawa M. [The role of cholesterol in the pathogenesis of Alzheimer's disease] Nippon Ronen Igakkai Zasshi. 2001 Nov;38(6):751-3.

Urakami K, Wakutani Y, Wada-Isoe K, Yamagata K, Adachi Y, Nakashima K. [Analysis of causative genes and genetic risk factor in Alzheimer's disease] Nippon Ronen Igakkai Zasshi. 2001 Nov;38(6):769-71.

Blondel A, Desgranges B, de la Sayette V, Schaeffer S, Benali K, Lechevalier B, Viader F, Eustache F. Disorders in intentional gestural organization in Alzheimer's disease: combined or selective impairment of the conceptual and production systems? Eur J Neurol. 2001 Nov;8(6):629-41.

Jellinger KA, Paulus W, Wrocklage C, Litvan I. Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease. Eur J Neurol. 2001 Nov;8(6):707-10.

Chen Q, Yoshida H, Schubert D, Maher P, Mallory M, Masliah E. Presenilin binding protein is associated with neurofibrillary alterations in Alzheimer's disease and stimulates tau phosphorylation. Am J Pathol. 2001 Nov;159(5):1597-602.

Gil R, Arroyo-Anllo EM, Ingrand P, Gil M, Neau JP, Ornon C, Bonnaud V. Self-consciousness and Alzheimer's disease. Acta Neurol Scand. 2001 Nov;104(5):296-300.

Melov S, Doctrow SR, Schneider JA, Haberson J, Patel M, Coskun PE, Huffman K, Wallace DC, Malfroy B. Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. J Neurosci. 2001 Nov 1;21(21):8348-53.

Nagatsuka Si S, Fukushi K, Shinotoh H, Namba H, Iyo M, Tanaka N, Aotsuka A, Ota T, Tanada S, Irie T. Kinetic analysis of [(11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. J Cereb Blood Flow Metab. 2001 Nov;21(11):1354-66.

Thal LJ. Cerebrovascular Disease Affects Noncognitive Symptoms in Alzheimer Disease. Arch Neurol. 2001 Nov;58(11):1939-1940.

Frisoni GB, Geroldi C. Cerebrovascular disease affects noncognitive symptoms in Alzheimer disease. Arch Neurol. 2001 Nov;58(11):1939-40.

Steinbart EJ, Smith CO, Poorkaj P, Bird TD. Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol. 2001 Nov;58(11):1828-31.

Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Alpha-synuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease. Arch Neurol. 2001 Nov;58(11):1817-20.

McGeer PL, McGeer EG. Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol. 2001 Nov;58(11):1790-2.

 

Schmidt ML, Zhukareva V, Perl DP, Sheridan SK, Schuck T, Lee VM, Trojanowski JQ. Spinal cord neurofibrillary pathology in Alzheimer disease and Guam Parkinsonism-dementia complex. J Neuropathol Exp Neurol. 2001 Nov;60(11):1075-86.

Le TV, Crook R, Hardy J, Dickson DW. Cotton wool plaques in non-familial late-onset Alzheimer disease. J Neuropathol Exp Neurol. 2001 Nov;60(11):1051-61.

Lermontova NN, Redkozubov AE, Shevtsova EF, Serkova TP, Kireeva EG, Bachurin SO. Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull Exp Biol Med. 2001 Nov;132(5):1079-83.

Lowery K. NICE guidelines unfair for Alzheimer's disease. Br J Nurs. 2001 Nov 8-21;10(20):1314.

Hartmann T. Cholesterol, A beta and Alzheimer's disease. Trends Neurosci. 2001 Nov;24(11 Suppl):S45-8.

Sisodia S S, Annaert W, Kim S H, De Strooper B. Gamma-secretase: never more enigmatic. Trends Neurosci. 2001 Nov;24(11 Suppl):S2-6.

Blauw G J, Bollen E L, van Buchem M A, Westendorp R G. Dementia at old age: a clinical end-point of atherosclerotic disease. Eur Heart J. 2001 Nov;3 Suppl N:N16-9.

Antérion CT, Honoré S, Cougny H, Grosmaitre C, Laurent B. [IContribution of lexical recall in the Set Test in Alzheimer disease screening] Rev Neurol (Paris). 2001 Nov;157(11 Pt 1):1377-82.

Michel BF, Estadieu MC, Gueriot C, Berthezène P, Allain H, Bongrand MC, Bonnefoy B, Bourrin JC, Chaix L, Graa K, Lejeune A, Messana M, Pras P, Ribiere J, Rihet P, Timon-David P, Tintignac A, Vincent S, Verdier JM, Gastaut JL. [Long-term treatment of Alzheimer's disease: followup of a cohort of 255 patients treated with lacrine for four years] Rev Neurol (Paris). 2001 Nov;157(11 Pt 1):1365-75.

Bertrand E, Brouillet E, Caillé I, Bouillot C, Cole G M, Prochiantz A, Allinquant B. A short cytoplasmic domain of the amyloid precursor protein induces apoptosis in vitro and in vivo. Mol Cell Neurosci. 2001 Nov;18(5):503-11.

Eder P, Reinprecht I, Schreiner E, Skofitsch G, Windisch M. Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: an immunohistochemical study on aged rats. Histochem J. 2001 Nov-Dec;33(11-12):605-12.

Skribanek Z, Baláspiri L, Mák M. Interaction between synthetic amyloid-beta-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. J Mass Spectrom. 2001 Nov;36(11):1226-9.

McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging. 2001 Nov-Dec;22(6):799-809.

Zandi PP, Breitner JC. Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging. 2001 Nov-Dec;22(6):811-7.

Mackenzie IR. Postmortem studies of the effect of anti-inflammatory drugs on Alzheimer-type pathology and associated inflammation. Neurobiol Aging. 2001 Nov-Dec;22(6):819-22.

Yermakova AV, O'Banion MK. Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec;22(6):823-36.

Grammas P, Ovase R. Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec;22(6):837-42.

McGeer EG, Yasojima K, Schwab C, McGeer PL. The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases. Neurobiol Aging. 2001 Nov-Dec;22(6):843-8.

Tenner AJ. Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging. 2001 Nov-Dec;22(6):849-61.

Papassotiropoulos A, Hock C, Nitsch RM. Genetics of interleukin 6: implications for Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec;22(6):863-71.

Perry RT, Collins JS, Wiener H, Acton R, Go RC. The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec;22(6):873-83.

Meda L, Baron P, Scarlato G. Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. Neurobiol Aging. 2001 Nov-Dec;22(6):885-93.

Sheng JG, Mrak RE, Jones RA, Brewer MM, Zhou XQ, McGinness J, Woodward S, Bales K, Paul SM, Cordell B, Griffin WS. Neuronal DNA damage correlates with overexpression of interleukin-1beta converting enzyme in APPV717F mice. Neurobiol Aging. 2001 Nov-Dec;22(6):895-902.

Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec;22(6):903-8.

Streit WJ, Conde JR, Harrison JK. Chemokines and Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec;22(6):909-13.

Mrak RE, Griffinbc WS. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec;22(6):915-22.

Potter H, Wefes IM, Nilsson LN. The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiol Aging. 2001 Nov-Dec;22(6):923-30.

Abraham CR. Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec;22(6):931-6.

Landreth GE, Heneka MT. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging. 2001 Nov-Dec;22(6):937-44.

Lue LF, Walker DG, Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging. 2001 Nov-Dec;22(6):945-56.

Walker DG, Lue LF, Beach TG. Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging. 2001 Nov-Dec;22(6):957-66.

Guo L, Sawkar A, Zasadzki M, Watterson DM, Van Eldik LJ. Similar activation of glial cultures from different rat brain regions by neuroinflammatory stimuli and downregulation of the activation by a new class of small molecule ligands. Neurobiol Aging. 2001 Nov-Dec;22(6):975-81.

Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W, Overmier JB, Hsiao-Ashec K, Frautschy SA, Cole GM. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging. 2001 Nov-Dec;22(6):983-91.

Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging. 2001 Nov-Dec;22(6):993-1005. ,

DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging. 2001 Nov-Dec;22(6):1007-12.

Yamada M. [Non-Alzheimer type dementia in elderly: senile dementia of the neurofibrillary tangle type(SD-NET)] No To Shinkei. 2001 Nov;53(11):1001-8.

Dimond B. Legal aspects of consent 16: statutory provisions and living wills. Br J Nurs. 2001 Nov 8-21;10(20):1327-9.

Howard R. Concepts of Alzheimer disease: biological, clinical, and cultural perspectives. Am J Psychiatry. 2001 Nov;158(11):1950.

Steinling M, Defebvre L, Duhamel A, Lecouffe P, Lavenu I, Pasquier F, Charpentier P. Is there a typical pattern of brain SPECT imaging in Alzheimer's disease? Dement Geriatr Cogn Disord. 2001 Nov-Dec;12(6):371-8.

Bogdanovic N, Zilmer M, Zilmer K, Rehema A, Karelson E. The Swedish APP670/671 Alzheimer's disease mutation: the first evidence for strikingly increased oxidative injury in the temporal inferior cortex. Dement Geriatr Cogn Disord. 2001 Nov-Dec;12(6):364-70.

Kergoat H, Kergoat MJ, Justino L, Robillard A, Bergman H, Chertkow H. Normal optic nerve head topography in the early stages of dementia of the Alzheimer type. Dement Geriatr Cogn Disord. 2001 Nov-Dec;12(6):359-63.

Tabarrini O, Cecchetti V, Temperini A, Filipponi E, Lamperti MG, Fravolini A. Velnacrine thiaanalogues as potential agents for treating Alzheimer's disease. Bioorg Med Chem. 2001 Nov;9(11):2921-8.

Neumann H. Control of glial immune function by neurons. Glia. 2001 Nov;36(2):191-9.

O'Brien HL, Tetewsky SJ, Avery LM, Cushman LA, Makous W, Duffy CJ. Visual mechanisms of spatial disorientation in Alzheimer's disease. Cereb Cortex. 2001 Nov;11(11):1083-92.

Amici S, Lanari A, Romani R, Antognelli C, Gallai V, Parnetti L. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina. Mech Ageing Dev. 2001 Nov 1;122(16):2057-62.

Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev. 2001 Nov;122(16):2041-55.

Amenta F, Parnetti L, Gallai V, Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches? Mech Ageing Dev. 2001 Nov;122(16):2025-40.

Vanmechelen E, Vanderstichele H, Hulstaert F, Andreasen N, Minthon L, Winblad B, Davidsson P, Blennow K. Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. Mech Ageing Dev. 2001 Nov;122(16):2005-11.

Padovani A, Borroni B, Colciaghi F, Pastorino L, Archetti S, Cottini E, Caimi L, Cattabeni F, Di Luca M. Platelet amyloid precursor protein forms in AD: a peripheral diagnostic tool and a pharmacological target. Mech Ageing Dev. 2001 Nov;122(16):1997-2004.

De Luigi A, Fragiacomo C, Lucca U, Quadri P, Tettamanti M, Grazia De Simoni M. Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech Ageing Dev. 2001 Nov;122(16):1985-95.

Bergamaschini L, Donarini C, Gobbo G, Parnetti L, Gallai V. Activation of complement and contact system in Alzheimer's disease. Mech Ageing Dev. 2001 Nov;122(16):1971-83.

Talesa VN. Acetylcholinesterase in Alzheimer's disease. Mech Ageing Dev. 2001 Nov;122(16):1961-9.

Sorbi S, Forleo P, Tedde A, Cellini E, Ciantelli M, Bagnoli S, Nacmias B. Genetic risk factors in familial Alzheimer's disease. Mech Ageing Dev. 2001 Nov;122(16):1951-60.

Sjögren M, Wallin A. Pathophysiological aspects of frontotemporal dementia--emphasis on cytoskeleton proteins and autoimmunity. Mech Ageing Dev. 2001 Nov;122(16):1923-35.

Watterson DM, Mirzoeva S, Guo L, Whyte A, Bourguignon JJ, Hibert M, Haiech J, Van Eldik LJ. Ligand modulation of glial activation: cell permeable, small molecule inhibitors of serine-threonine protein kinases can block induction of interleukin 1 beta and nitric oxide synthase II. Neurochem Int. 2001 Nov-Dec;39(5-6):459-68.

Combs CK, Bates P, Karlo JC, Landreth GE. Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem Int. 2001 Nov-Dec;39(5-6):449-57.

Harris-White ME, Chu T, Miller SA, Simmons M, Teter B, Nash D, Cole GM, Frautschy SA. Estrogen (E2) and glucocorticoid (Gc) effects on microglia and A beta clearance in vitro and in vivo. Neurochem Int. 2001 Nov-Dec;39(5-6):435-48.

LaDu MJ, Shah JA, Reardon CA, Getz GS, Bu G, Hu J, Guo L, Van Eldik LJ. Apolipoprotein E and apolipoprotein E receptors modulate A beta-induced glial neuroinflammatory responses. Neurochem Int. 2001 Nov-Dec;39(5-6):427-34.

DeMattos RB, Brendza RP, Heuser JE, Kierson M, Cirrito JR, Fryer J, Sullivan PM, Fagan AM, Han X, Holtzman DM. Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice. Neurochem Int. 2001 Nov-Dec;39(5-6):415-25.

Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int. 2001 Nov-Dec;39(5-6):409-13.

Masliah E, Ho G, Wyss-Coray T. Functional role of TGF beta in Alzheimer's disease microvascular injury: lessons from transgenic mice. Neurochem Int. 2001 Nov-Dec;39(5-6):393-400.

Benveniste EN, Nguyen VT, O'Keefe GM. Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem Int. 2001 Nov-Dec;39(5-6):381-91.

Town T, Tan J, Mullan M. CD40 signaling and Alzheimer's disease pathogenesis. Neurochem Int. 2001 Nov-Dec;39(5-6):371-80.

Nilsson LN, Das S, Potter H. Effect of cytokines, dexamethasone and the A/T-signal peptide polymorphism on the expression of alpha(1)-antichymotrypsin in astrocytes: significance for Alzheimer's disease. Neurochem Int. 2001 Nov-Dec;39(5-6):361-70.

Chang JW, Young DA, Coleman PD, O'Banion MK. Two-dimensional gel analysis of secreted proteins induced by interleukin-1 beta in rat astrocytes. Neurochem Int. 2001 Nov-Dec;39(5-6):349-59.